Sergio Muñiz Castrillo, MD PhD
Mon principal sujet de recherche était l'immunogénétique dans les encéphalites auto-immunes et les syndromes neurologiques paranéoplasiques. J'ai mené plusieurs études pour déterminer si ces troubles étaient liés à l'antigène leucocytaire humain (HLA), ainsi que les associations entre HLA et les caractéristiques cliniques et immunologiques. Ce travail a constitué ma thèse de doctorat. De plus, j'ai mené ou participé à d'autres études portant sur les aspects cliniques, la détection des anticorps ou les complications des inhibiteurs du point de contrôle immunitaire, entre autres. J'ai également été impliqué dans les activités cliniques et de laboratoire du Centre de Référence.
Le temps que j'ai passé à Lyon a été extrêmement important pour moi tant sur le plan professionnel que personnel. J'ai eu l'opportunité de développer une carrière scientifique dans un environnement motivant, convivial et solidaire.
Publications & Revues durant mon séjour:
Peris Sempre V, Muñiz-Castrillo S, and al. Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2022. DOI: https://doi.org/10.1212/NXI.0000000000001140 (WP3)
Lardeux P, and al. Core cerebrospinal fuid biomarker profle in anti‑LGI1 encephalitis. Journal of neurology. 2021. https://doi.org/10.1007/s00415-021-10642-2 (WP2)
Vogrig A, Péricart S, and al. Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis. Brain Communications. 2021. https://doi.org/10.1093/braincomms/fcab185 (WP2)
Muñiz-Castrillo S, Hedou J, and al. Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. Brain, 2021; awab153, https://doi.org/10.1093/brain/awab153 (WP3)
Muñiz‑Castrillo S, Haesebaert J and al. Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021. DOI: https://doi.org/10.1212/NXI.0000000000000974 (WP3)
Muñiz‑Castrillo S, Vogrig A and al. Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study. Journal of neurology. 2021. https://doi.org/10.1007/s00415-021-10424-w (WP3)
Vogrig A, and al. Cranial Nerve Disorders Associated with Immune Checkpoint Inhibitors. Neurology. 2020. doi.org/10.1212/WNL.0000000000011340 (WP2)
Hébert J, Riche B and al. Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm. 2020; 7 (6). https://doi.org/10.1212/NXI.0000000000000883 (WP1)
Muñiz‑Castrillo S, Joubert B, and al. Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features. J Neurol Neurosurg Psychiatry. 2020; 0:1–9. doi.org/10.1136/jnnp-2020-323226 (WP3)
Muñiz‑Castrillo S, Vogrig A, Joubert B, and al. Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies. Cerebellum. 2020; 19 715-721. https://doi.org/10.1007/s12311-020-01159 (WP2)
Vogrig A, Muñiz‑Castrillo S, Joubert B, and al. Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry. 2020; 91:772-778. doi: 10.1136/jnnp-2020-323212 (WP2)
Simard C, Vogrig A, Joubert B, and al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm. 2020; 7:e699. DOI:https://doi.org/10.1212/NXI.0000000000000699 (WP2)
Déchelotte B, Muñiz‑Castrillo S, Joubert B, and al. Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurological syndromes. Neurol Neuroimmunol Neuroinflamm. 2020; 7(3):e701. https://doi.org/10.1212/NXI.0000000000000701 (WP2)
Muñiz‑Castrillo S, Ambati A, Dubois V, and al. Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies. J Neurol. 2020; 267:1906-1911. http://dx.doi.org/10.1007/s00415-020-09782-8 (WP3)
Muñiz‑Castrillo S, Vogrig A, and al. Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses. The Cerebellum. 2022.https://doi.org/10.1007/s12311-021-01363-3 (WP2)
Ciano-Petersen N, Muñiz‑Castrillo S, and al. Immunomodulation in the acute phase of autoimmune encephalitis. Revue neurologique. 2022. https://doi.org/10.1016/j.neurol.2021.12.001 (WP2)
Ciano-Petersen N and al. Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Int J Mol Sci. 2021. doi: 10.3390/ijms222313127 (WP2)
Graus F, Vogrig A, Muñiz-Castrillo S, and al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021. DOI: 10.1212/NXI.0000000000001014 (WP2)
Vogrig A, Muñiz-Castrillo S, and al. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update. Journal of neurology. 2021. https://doi.org/10.1007/s00415-021-10870-6 (WP2)
Fels E, Muñiz‑Castrillo S, and al. Role of LGI1 protein in synaptic transmission: From physiology to pathology. Neurobiology of disease. 2021. doi: 10.1016/j.nbd.2021.105537 (WP2)
Muñiz-Castrillo S, and al. Diagnostic des encéphalites auto-immunes. Pratique Neurologique – FMC 2020. doi.org/10.1016/j.praneu.2020.08.006 (WP2)
Vogrig A, Muñiz‑Castrillo S, Desestret V. Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors. Ther Adv Neurol Disord. 2020; 13:1-15. https://doi.org/10.1177/1756286420932797 (WP2)
Muñiz‑Castrillo S, Vogrig A, Honnorat J. Associations between HLA and autoimmune neurological diseases with autoantibodies. Autoimmun Highlights. 2020; 11:2. https://doi.org/10.1186/s13317-019-0124-6 (WP3)
